Abstract
The opioid receptor-like 1 (ORL1) system has attracted a lot of attention owing to its diverse physiological role and by its close structural proximity toward the classical opioid receptors. Even though they share a close sequence similarity, the ligand recognition pattern for the ORL1 receptor and the classical opioid receptors remains highly distinct. In addition, functional diversification observed between the ORL1 receptor system and classical opioid receptors clearly indicates that subtle changes in the structural makeup of a receptor are enough to delineate them. A clear understanding of the structural requirements for ligand selectivity by classical opioid receptors and identification of a common “opioid binding pocket” has not been achieved yet. At this juncture, the ORL1 receptor system presents itself as a potential tool in the quest for elucidating critical elements directing ligand selectivity. The current paper is a compilation of several sitedirected mutagenesis studies conducted on the ORL1 receptor system. The mutagenesis studies concentrated on the transmembrane domain residues are reported with the changes observed in terms of both binding and functional activation of the receptor. Given the critical role played by this G-protein coupled receptor, molecular level understanding of this ORL1 receptor system would aid in rational design and development of agonists and antagonists with multiple therapeutic applications.
Keywords: g-protein coupled receptors(gpcrs), cdna library, opioid receptor agonist, trans-membrane domain, mutagenesis, nociceptin, ethylketocyclazocine, ligands, phenylalanine residues
Current Topics in Medicinal Chemistry
Title: Opioid Receptor-Like 1 (ORL1) Molecular “Road Map” to Understanding Ligand Interaction and Selectivity
Volume: 5 Issue: 3
Author(s): Ashok E. Philip, Jacques H. Poupaert and Christopher R. McCurdy
Affiliation:
Keywords: g-protein coupled receptors(gpcrs), cdna library, opioid receptor agonist, trans-membrane domain, mutagenesis, nociceptin, ethylketocyclazocine, ligands, phenylalanine residues
Abstract: The opioid receptor-like 1 (ORL1) system has attracted a lot of attention owing to its diverse physiological role and by its close structural proximity toward the classical opioid receptors. Even though they share a close sequence similarity, the ligand recognition pattern for the ORL1 receptor and the classical opioid receptors remains highly distinct. In addition, functional diversification observed between the ORL1 receptor system and classical opioid receptors clearly indicates that subtle changes in the structural makeup of a receptor are enough to delineate them. A clear understanding of the structural requirements for ligand selectivity by classical opioid receptors and identification of a common “opioid binding pocket” has not been achieved yet. At this juncture, the ORL1 receptor system presents itself as a potential tool in the quest for elucidating critical elements directing ligand selectivity. The current paper is a compilation of several sitedirected mutagenesis studies conducted on the ORL1 receptor system. The mutagenesis studies concentrated on the transmembrane domain residues are reported with the changes observed in terms of both binding and functional activation of the receptor. Given the critical role played by this G-protein coupled receptor, molecular level understanding of this ORL1 receptor system would aid in rational design and development of agonists and antagonists with multiple therapeutic applications.
Export Options
About this article
Cite this article as:
Philip E. Ashok, Poupaert H. Jacques and McCurdy R. Christopher, Opioid Receptor-Like 1 (ORL1) Molecular “Road Map” to Understanding Ligand Interaction and Selectivity, Current Topics in Medicinal Chemistry 2005; 5 (3) . https://dx.doi.org/10.2174/1568026053544489
DOI https://dx.doi.org/10.2174/1568026053544489 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeted Biomedical Treatment for Autism Spectrum Disorders
Current Pharmaceutical Design Individual Differences in Novelty-Seeking and Behavioral Responses to Nicotine: A Review of Animal Studies
Current Drug Abuse Reviews Recent Updates on Current and Upcoming Biomarkers for Cardiovascular Diseases
Current Pharmaceutical Design Anticipation in Lynch Syndrome: Where We Are Where We Go
Current Genomics Biomarkers of Alzheimer's Disease Risk in Peripheral Tissues; Focus on Buccal Cells
Current Alzheimer Research Nitric Oxide and Major Depressive Disorder: Pathophysiology and Treatment Implications
Current Molecular Medicine Emotions and the Body
Central Nervous System Agents in Medicinal Chemistry Characterising the Folding Pathways of Topologically Knotted Proteins
Current Physical Chemistry Ectonucleotidases and Nucleotide/Nucleoside Transporters as Pharmacological Targets for Neurological Disorders
CNS & Neurological Disorders - Drug Targets Resilience to Alzheimer's Disease: The Role of Physical Activity
Current Alzheimer Research Molecule of the Month
Current Topics in Medicinal Chemistry Linking Fold, Function and Phylogeny: A Comparative Genomics View on Protein (Domain) Evolution
Current Genomics Interactions Between Haptic and Visual Perceptions of Fine Surface Texture
Neuroscience and Biomedical Engineering (Discontinued) Approaches to Stabilize Amorphous Form - A Review
Current Drug Therapy Curcumin and Endothelial Function: Evidence and Mechanisms of Protective Effects
Current Pharmaceutical Design Update on the Therapy of Behçets Disease
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Polyunsaturated Fatty Acids in Pregnancy and Metabolic Syndrome: A Review
Current Pharmaceutical Biotechnology The Mechanism of Action of Salsolinol in Brain: Implications in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Graphene Modified Molecular Imprinting Electrochemical Sensor for Determining the Content of Dopamine
Current Analytical Chemistry Micro-/nano-electroporation for active gene delivery
Current Pharmaceutical Design